Pharmaceutical administration form for peptides, process for its preparation, and use
View Patent ↗The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.
1. A pharmaceutical composition for parenteral administration, comprising:
(a) a pharmaceutically effective amount of the peptidic LHRH antagonist salt cetrorelix acetate, in a concentration of 2.5 mg/ml total solution;
(b) a pharmaceutically acceptable acid and % in total solution thereof, selected from the group consisting of gluconic acid of 0.00710%, 0.071, or 0.71%, or glucaric acid or galacturonic acid of 2.5%, wherein the pharmaceutically acceptable acid is present as free acid and is in an amount capable of imparting a pH of 2.5, 2.6, 3.1, 3.7, or 4.5 to the composition and suppressing aggregation of cetrorelix acetate; and
(c) a carrier, wherein the carrier is water or an aqueous solvent mixture.
2. The pharmaceutical composition of claim 1 , further comprising an excipient.
3. The pharmaceutical composition of claim 2 , wherein the excipient comprises gluconic acid, glucuronic acid, galacturonic acid, glucaric acid, citric acid, ascorbic acid, or an amino acid.
4. The pharmaceutical composition of claim 2 , wherein the excipient comprises polyethylene glycol 12(hydroxy)stearate (Solutol®), polyoxyethylene ricinoleate (Cremophor®), polysorbates, poloxamers, phospholipids, lecithins, or a preservative.
5. The pharmaceutical composition of claim 2 , wherein the excipient comprises albumins, polyethylene glycols, cellulose derivatives, starch derivatives or polyvinylpyrrolidone.
6. The pharmaceutical composition of claim 2 , wherein the excipient comprises cyclodextrins or its derivatives, or sugar alcohols.
7. The pharmaceutical composition of claim 2 , wherein the excipient comprises urea or other chaotropic substances.
8. The pharmaceutical composition of claim 1 , wherein the release of cetrorelix acetate is delayed by the use of a polymer.
9. The pharmaceutical composition of claim 8 , wherein the Polymer is a homo- or copolymer of lactic or glycolic acid.
10. The pharmaceutical composition of claim 4 , wherein the preservative is benzalkonium chloride or phenylmercury acetate.
11. The pharmaceutical composition of claim 6 , wherein the sugar alcohol is mannitol.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition for parenteral administration is an injection preparation.
13. The pharmaceutical composition of claim 12 , wherein the injection preparation is for subcutaneous injection.
14. The pharmaceutical composition of claim 2 , wherein the excipient is independently selected from mannitol, polyethylene glycol 12-(hydroxyl)stearate, polyoxyethylene ricinoleate, glycine, citric acid and cyclodextrin.
15. The pharmaceutical composition of claim 1 manufactured by reconstitution of a lyophilisate of the cetrorelix acetate, wherein the reconstitution medium is water containing a pharmaceutically acceptable acid independently selected from gluconic acid or galacturonic acid.
16. The pharmaceutical composition of claim 1 manufactured by reconstitution of a lyophilisate of cetrorelix acetate, wherein the reconstitution medium is water containing a pharmaceutically acceptable acid independently selected from gluconic acid, glucaric acid and galacturonic acid.
17. The pharmaceutical composition of claim 1 manufactured by reconstitution of a lyophilisate consisting of the Cetrorelix salt and an excipient independently selected from mannitol, polyethylene glycol 12- (hydroxyl)stearate, polyoxyethylene ricinoleate, glycine, citric acid and cyclodextrin, wherein the reconstitution medium is water containing a pharmaceutically acceptable acid independently selected from gluconic acid, glucaric acid and galacturonic acid.